(Q40308348)

19 September 2017

title

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial (English)

1 reference

19 September 2017

1 reference

2

Rodryg Ramlau

1 reference

19 September 2017

Elisabeth Quoix

1

1 reference

19 September 2017

Virginie Westeel

3

1 reference

19 September 2017

Zsolt Papai

4

1 reference

19 September 2017

Anne Madroszyk

5

1 reference

19 September 2017

Alain Riviere

6

1 reference

19 September 2017

Piotr Koralewski

7

1 reference

19 September 2017

Jean-Luc Breton

8

1 reference

19 September 2017

Erich Stoelben

9

1 reference

19 September 2017

Denis Braun

10

1 reference

19 September 2017

Didier Debieuvre

11

1 reference

19 September 2017

Hervé Lena

12

1 reference

19 September 2017

Marc Buyse

13

1 reference

19 September 2017

Marie-Pierre Chenard

14

1 reference

19 September 2017

Bruce Acres

15

1 reference

19 September 2017

Gisèle Lacoste

16

1 reference

19 September 2017

Bérangère Bastien

17

1 reference

19 September 2017

Annette Tavernaro

18

1 reference

19 September 2017

Nadine Bizouarne

19

1 reference

19 September 2017

Jean-Yves Bonnefoy

20

1 reference

19 September 2017

Jean-Marc Limacher

21

1 reference

19 September 2017

publication date

21 October 2011

1 reference

Lancet Oncology Commission

19 September 2017

published in

1 reference

19 September 2017

volume

12

1 reference

19 September 2017

issue

12

1 reference

19 September 2017

page(s)

1125-1133

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

A transcribed gene, containing a variable number of tandem repeats, codes for a human epithelial tumor antigen. cDNA cloning, expression of the transfected gene and over-expression in breast cancer tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

Molecular targeted agents and biologic therapies for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

Functions of natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

Regulatory natural killer cells: new players in the IL-10 anti-inflammatory response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970259-5

7 January 2021

10.1016/S1470-2045(11)70259-5

Identifiers

DOI

1 reference

19 September 2017

1 reference